Another study also found that blocking RIPK1 may provide a treatment option for OPTN mutation-mediated ALS by inhibiting axonal degeneration caused by inflammation and necroptosis (Ito et al., 2016). This evidence concerns the gene OPTN and amyotrophic lateral sclerosis.